Background: SAMHD1 inhibits HIV-1 reverse transcription by decreasing the pool of intracellular deoxynucleotides in myeloid and lymphoid cells. The activity of the HIV-1 restriction factor SAMHD1 is controlled by cyclin-dependent kinase (CDK)-mediated phosphorylation. However, the exact mechanism of SAMHD1 regulation in primary cells is unclear. Methodology: Human primary monocytes obtained from PBMC were differentiated into macrophages with M-CSF. CD4+ T lymphocytes were obtained from PBMC and stimulated with PHA/IL-2. Cells were pre-treated with CDK inhibitors and then infected with a GFP-expressing HIV-1 or R5-tropic virus BaL. Proviral DNA formation was measured by quantitative PCR and infection assessed by flow cytometry. SAMHD1 was degraded treating cells with viral-like particles carrying Vpx (VLP-Vpx). Results: Pan CDK inhibitors roscovitine and purvalanol A show in vitro activity against several CDK, including CDK2 and AT7519 is a preferential inhibitor of CDK2. These CDK inhibitors reduced SAMHD1 phosphorylation in macrophages and CD4+ T lymphocytes as measured by Western blot analysis. HIV-1 replication was blocked in primary macrophages by roscovitine (47.3%}3.9; n=4), purvalanol A (55.7%}15.7; n=4) and AT7519 (66.4%}3.8; n=4) at subtoxic concentrations as measured by the colorimetric MTT assay. CDK inhibitors blocked the formation of proviral DNA formation, indicating an effect on the reverse transcription step. Similar results were obtained in primary CD4+ T lymphocytes. In addition to these broad-spectrum CDK inhibitors, we tested the antiviral activity of palbociclib, a potent and selective CDK6 inhibitor. Palbociclib potently inhibited SAMHD1 phosphorylation, HIV-1 reverse transcription and HIV-1 replication (99.5%}0.2; n=4). Notably, treatment of macrophages with palbociclib led to reduced CDK2 activation, measured as the phosphorylation of the T-loop at the Thr160. The antiviral effect of all CDK inhibitors was lost when SAMHD1 was degraded using VLPVpx, providing further evidence for a role of SAMHD1 in mediating the antiretroviral effect. Conclusions: Our results indicate that SAMHD1-mediated restriction of HIV-1 infection is controlled by CDK as previously suggested, but point to a preferential role for CDK2 and CDK6 as mediators of SAMHD1 activation. Our study provides a new signalling pathway susceptible for the development of new therapeutic approaches against HIV-1 infection.